agnostic tests for influenza virus type A obtained by other investigators ranges from 43% to 93%, with a specificity >90% . 8, 10, 15, 16 The sensitivity and specificity of DAS-ELISA . observed in the present study as compared with the VIT results is 93% and 92%, respectively. The positive predictive value was also high, suggesting a low rate of false positives. Eleven samples were positive by DAS-ELISA and negative by VIT. These would be considered false positives based on the results of VIT. However, these samples may be true positives because DAS-ELISA can detect nonviable virus particles or may detect low level of virus. The kappa index was used to determine the concordance between the 2 methods and to assess the reliability of the observed agreement, which does not correct the agreement expected by chance.ll In the present study, the index of agreement (92%) was good, and the kappa index between DAS-ELISA and VIT also showed an excellent agreement between the two assays. 9 The DAS-ELISA described in this study is a potentially viable alternative to the VIT, and the results are in excellent agreement with those of the VIT. The DAS-ELISA is sensitive and rapid, does not require considerable expertise, and could be adapted to large-scale epidemiological studies. More sensitive detection might be achieved by the use of a combination of NP monoclonal antibodies. The use of a combination of monoclonal antibodies may permit the direct detection of low levels of antigen in samples.
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Bean WJ: 1984 440-443 (1993) Differential diagnostic blocking ELISA for use in conjunction with modified-live IBRV gIII-deleted marker vaccine Saul Kit, Haruki Otsuka, Malon Kit The development of safe and efficacious gene-deleted marker vaccines and companion differential diagnostic tests has stimulated programs to control and eradicate pseudorabies (PR) in swine 9 and infectious bovine rhinotracheitis -(IBR) in cattle. 8 The PR marker vaccine, OMNIMARK-PRV a developed in our laboratory, was attenuated by deletions in the thymidine kinase (TK) 9 and glycoprotein III (gIII) 4 genes and has been licensed in the USA and Japan for use in 3-dayold pigs and in pregnant sows in all stages of gestation. The companion anti-PR virus (PRV) gIII blocking enzyme-linked immunosorbent assay (ELISA)" has the high sensitivity and specificity required to distinguish between vaccinated and infected swine. 5, 7, 13, 14 The analogous genetically engineered IBR marker vaccine, IBRV(NG)dltkdlgIII, likewise contains attenuating TK 8 and gIII 12 gene deletions and utilizes gIII as a marker. 8 The safety and efficacy of the IBRV(NG)dltkdlgIII vaccine and its compatibility with IBR eradication programs has recently been demonstrated. 3 The purposes of the present report are to describe the anti-IBR virus (IBRV) gIII blocking ELISA used in conjunction with this gene-deleted IBR marker vaccine and to discuss the choice and comparative advantages of gIII marker systems.
The design of the anti-IBRV gIII blocking ELISA was based on that of a highly sensitive anti-PRV gIII blocking ELISA 5 and the first generation anti-IBRV gIII blocking ELISA. 10 Undiluted test sera are used to block the binding of anti-gIII mouse monoclonal antibody-horse radish peroxidase conjugates (moMCA-HRPO). Hence, time consuming and laborious dilutions of test sera and potential dilution errors are avoided. The blocking ELISA described here differs in 2 important ways from the first generation test previously described. 10 First, the antigen used to coat wells of 12-well strips was prepared by partially purifying IBRV (Los Angeles) in sucrose density gradients (2.5 ml 20% [w/w] sucrose solution layered over 0.5 ml 60% [w/w] sucrose solution cushion) and not by preparing Triton X-100 extracts of IBRV-infected cells. 10 Triton X-100 in extracts decreases sensitivity; therefore, this change enhanced the sensitivity of the test. However, the partially purified IBRV preparations contain several IBRV glycoproteins besides gIII. The heterologous glycoproteins can reduce specificity, presumably by binding antibodies that sterically hinder anti-gIII moMCA-HRPO binding. Unlike the case of the anti-PRV gIII blocking ELISA, 7 a clone-purified IBRV gIII was not available for coating test wells. To circumvent the problem of reduced specificity, 0.1 ml of pretested diluted gIII-negative bovine serum from cattle immunized with the gIII-negative IBRV vaccine 3 was added to each well, the strips were incubated overnight at 4 C, the fluid was removed (no washing), and aliquots (0.1 ml) of test sera and of the negative and positive control sera were added to appropriate wells. In each assay, 2 wells were employed for positive controls (bovine anti-IBRV serum), 2 wells for negative controls (gamma globulin [GG]-free bovine fetal serum [BFS]), and 2 wells served as blank wells (no antigen). Negative serum was added to 1 blank well and a positive serum to the other blank well. The plates were incubated for 2 hours at 21-25 C, fluid was removed, and the wells were rinsed 3 times with TEN (50mM Tris-HCl, pH 7.2, 150 mm NaCl, 1 mm ethylenediaminetetraacetic acid) buffer. The plates were inverted and tapped several times on a clean paper towel to remove excess fluids from the wells. IRBV anti-gIII moMCA-HRPO (0.1 ml) was added to each well, and the plates were covered, incubated at 21-25 C for 30 minutes, and rinsed 5 times with TEN buffer, tapping dry between washes. Finally, 0.1 ml of premixed TMB substrate solutions I and II c were added to all of the wells, the plates were incubated at 21-25 C for 20 minutes, and 0.05 ml of a stop solution containing 0.01% sodium azide was added to each well. Color was analyzed by reading the absorbance Blocking ELISA analyses are generally considered to be more sensitive than virus neutralization (VN) tests. 7 Hence, sera with negative VN titers for IBRV may not necessarily be negative for IBRV antibodies and therefore may not be appropriate as negative controls. To establish the cutoff values for negative and positive S/N values, analyses were performed on 1) bovine antisera to bovine viral diarrhea virus, coronavirus, respiratory syncitial virus, and Parainfluenza-3 obtained from gnotobiotic cattle; d 2) antisera to vesicular stomatitis virus and rotavirus obtained from "normal" cattle; d 3) antisera to bovine herpesvirus 2, PRV, and equine herpesvirus 1; and 4) "normal" horse and rabbit sera. The S/N values for these sera varied from 0.81 to 1.03, indicating that the blocking of the anti-gIII moMCA-HRPO was less than 20%. The S/N value for a bovine anti-IBRV sera with a VN titer of 1:64 was 0.07. Fifty feedlot sera from cattle with VN titers of 1:2-1:256, hence definitely positive for IBRV, all exhibited S/N values of <0.7 (Fig. 1) . On the basis of these analyses, the data to be described, and our previous experience with the PRV anti-gIII blocking ELISA test, 7 S/N values of <0.7 were tentatively considered positive for IBRV gIII antibodies and S/N values of > 0.7 were considered negative. Sera with S/N values of 0.65-0.75 are considered borderline (±), requiring repetition of the assays or assays on additional sera collected from the same animals.
All sera from feedlot cattle e that had been vaccinated with a gIII-positive commercial vaccine, including those with negative VN titers of < 1:4 prior to vaccination, exhibited strongly positive S/N values of <0.7, as expected (Fig. 2) . Analyses of 650 nm. The absorbance of the blank wells (about 0.05) on 116 sera collected from feedlot cattle with negative VN was subtracted from the absorbance readings of the other titers of < 1:2 or < 1:4 e indicated that about 80% of these wells. The antigen and moMCA-HRPO concentrations were sera had negative S/N values of > 0.7, but several sera showed adjusted so that the absorbance values of the negative GG-strongly positive S/N values (<0.5) (Fig. 3) . A total of about free BFS controls were about 1.0-1.5. The absorbance value 20% of the sera had positive S/N values. Eighty-four of these of the positive controls (gIII-positive bovine anti-IBRV sera) sera were from a herd showing evidence of distress on arrival at the feedlot. IBRV was isolated from 7/10 buffy coat samples taken at random, and 14/84 sera from this herd were seropositive by VN, conclusively indicating that the herd was experiencing an IBRV outbreak. Thus, it is not surprising that some of the sera had negative VN but positive S/N values.
Three New Zealand rabbits twice immunized with IBRV(NG)dltkdlgIII developed VN antibodies by 14 days postvaccination and showed anamnestic responses after the second vaccination and after challenge with virulent IBRV (Cooper/USDA). 10 The S/N values for these rabbit sera were negative after the 2 vaccinations but became positive 6 days after challenge with IBRV (Cooper/USDA) (data not shown). As part of a safety and efficacy study, cattle from a specificpathogen-free herd were immunized with IBRV-(NG)dltkdlgIII, and at 30 days after vaccination they were challenged with virulent IBRV (Cooper/USDA). 3 Prior to vaccination, VN titers were negative (< 1:2). At 30 days postvaccination, 9112 vaccinated cattle exhibited positive VN titers of 1:2-1 : 16 (Table 1) . Marked increases in the VN titers were observed at 7 and 14 days after challenge with virulent IBRV (Cooper/USDA). The VN titers of a nonvaccinated control (no. 9140) was negative (< 1:2) at 7 days after challenge and attained a titer of 1: 16 at 14 days postchallenge. The blocking ELISA S/N values were negative (> 0.70) prior to vaccination and at 30 days postvaccination. At 7 days postchallenge, 5 of the 12 vaccinated animals had weakly positive S/N values (0.66-0.69), and 2 sera were borderline negative (0.71, 0.72). The S/N value of the nonvaccinated animal (no. 9140) was negative 7 days after challenge. The S/N values of all vaccinated animals and of the nonvaccinated animal were positive for gIII antibodies at 14 days after challenge (Table 1 ) and at 22 and 28 days after challenge (data not shown).
The data presented indicate that the anti-IBRV blocking ELISA is sensitive and specific and suggest that the test could be useful in screening for natural exposure to IBRV. The test distinguishes serologically between vaccinated cattle and those infected with IBRV field strains, as required for IBRV control and eradication programs.
Glycoprotein III was chosen as the deletion marker for this IBRV vaccine/companion test kit system based upon previous experience with the OMNIMARK-PRV and anti-PRV gIII blocking ELISA system. The PRV gIII blocking ELISA is more reliable than the gX ELISA for detecting latent PRV infections of naturally infected feral pigs 14 or virulent virusinfected vaccinated pigs. 16 Glycoprotein III, although nonessential for IBRV [PRV and Herpes simplex virus (HSV)] replication, is a major virion envelope glycoprotein, visible by electron microscopy as a spike on the surface of virus particles, 8, 11 and is strongly recognized by the sera of infected animals.* Deletion of gIII does not compromise the efficacy of IBRV vaccines 3,12 or PRV 9 vaccines. Even though gIII deletion removes 1 important antigen used to induce humoral and cellular immunity, the 6-9 remaining viral glycoproteins and the numerous virus-specific nonglycoproteins provide ample targets for induction of protective host immunologic responses. The IBRV gIII and homologous PRV gIII and HSV gC glycoproteins function only early in the infective process by promoting virus attachment to heparan proteoglycan receptors on the cell surface, but they are not critical to that process. 1, 8, 11, 12 IBRV gI and gIV have accessory roles in the attachment process. Glycoprotein III-deleted herpesviruses initiate infections more slowly than do gIII-positive viruses but replicate to high titers. By contrast, PRV gI, the homolog of IBRV ge, which has commonly been used as a deletion marker in many commercial PRV vaccines, promotes cell fusion and virus spread via direct cell-to-cell transmission. 17 The implications are that gIII-deleted IBRV and PRV marker vaccines will tend to spread to adjacent cells by fusion of infected cell membranes with uninfected cell membranes (syncytia), i.e., by an antibody-insensitive process promoted by IBRV ge (PRV gI), whereas marker vaccines with IBRV ge (PRV gI) deletions will spread to nearby and distant cells mainly by a gIII-mediated, antibody-sensitive extracellular route. 17 Maternal antibodies interfere with active immunization of animals against viral diseases? As emphasized by van Oirschot (p. 407), 15 "To overcome the interference of maternal antibodies with the induction of active immunity after vaccination is one of the greatest challenges for veterinary vaccinologists." The choice of the marker in vaccine/companion diagnostic test systems is relevent to the problem of maternal antibody interference. With PRV vaccines, the use of gI as a marker mandates immunization strategies that delay active immunization until after maternal antibodies have largely disappeared. Also, animals that receive maternal antibodies from mothers immunized with PRV gI-deleted marker vaccines may fail to seroconvert to PRV gI-antibodies after experimental infection with virulent virus. 15 Furthermore, animals that develop high levels of VN antibodies after immunization with PRV gI-deleted marker vaccines may not develop detectable PRV gI antibodies after virulent virus infection; 2,6 therefore, animals latently infected with virulent virus may go undetected. Because gIII-deleted IBRV and PRV vaccines rely on the antibody insensitive mode of cellto-cell spread by membrane fusion, gIII-deleted marker vaccines for immunization of young animals may offer a means for circumventing the maternal antibody problem. Experiments on the efficacy of immunizing maternally immune piglets with a gIII-deleted PRV vaccine have recently been completed and support this hypothesis (B. Lawhom, S. McConnell, M. Kit, and S. Kit, in preparation) .
